| アブストラクト | PURPOSE: To estimate the proportion of osteoporosis patients in whom initiating strontium ranelate treatment, under new EMA guidelines, should be contraindicated because of a history of cardiovascular events or risk for cardiovascular events. MATERIALS AND METHODS: This was a retrospective analysis of medical and pharmacy claims using the Clinical Practice Research Datalink database. Patients were included if they had >/=1 prescription of strontium from September 1, 2008 to August 31, 2013, were aged >/=50 as of the index date (the date of the first ever strontium ranelate prescription), and had >/=1 year of medical records pre-index. Cardiovascular events occurring any time pre-index were identified, which included ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, and peripheral arterial disease. Cardiovascular risk factors assessed included 1) diabetes or hypertension any time pre-index; 2) hyperlipidemia in the 12 months pre-index; or 3) obesity in the 12 months pre-index. RESULTS: A total of 7,474 patients were included: 90.4% were women, with an average age of 76.5 years, and 84.5% used osteoporosis therapy, either bisphosphonates or non-bisphosphonates, prior to strontium initiation. A total of 23.6% of patients experienced >/=1 cardiovascular event prior to strontium initiation; the rate was lower among female patients than in male patients (22.4% vs 35.3%, P<0.01). A total of 45.9% had risk factors for cardiovascular events (without cardiovascular event history). CONCLUSION: More than one-fifth of osteoporosis patients in the UK who used strontium had a cardiovascular event history, and one-half had cardiovascular risk factors prior to strontium initiation. |
|---|
| ジャーナル名 | International journal of women's health |
|---|
| Pubmed追加日 | 2015/11/26 |
|---|
| 投稿者 | Yu, Jingbo; Tang, Jackson; Li, Zhiyi; Sajjan, Shiva; O'Regan, Christopher; Modi, Ankita; Sazonov, Vasilisa |
|---|
| 組織名 | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc.,;Kenilworth, NJ, USA.;Asclepius Analytics Ltd., Wanchai, Hong Kong.;Merck Sharp & Dohme Corp., Hoddeson, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26604831/ |
|---|
